The therapy was designed to reduce the production of mutant alpha-1 antitrypsin protein, which progresses the liver disease.
Takeda and Arrowhead will co-develop the therapy. If approved, Takeda will lead commercialization efforts and split potential profits in a 50/50 structure.
Arrowhead will receive an upfront payment of $300 million, with the potential to earn $740 million in regulatory and commercial milestones.
More articles on surgery centers:
The 3 things facilities should do now to prepare for the 2021 CMS Physician Fee Schedule
6 must-know coding updates in 2020
Blue Cross North Carolina, Wake Forest collaborate on new insurance network
